|Ms. Meenu Chhabra||Pres, CEO & Director||772.5k||N/A||1972|
|Dr. Benito Munoz||Chief Scientific Officer||477.27k||N/A||1962|
|Dr. Po-Shun Lee||Consultant||486.95k||N/A||1969|
|Mr. Eric D. Larson||Principal Financial Officer & Principal Accounting Officer||N/A||N/A||1970|
|Ms. Sheila Gilbride Wilson M.B.A.||Chief Operating Officer||N/A||N/A||1958|
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The company's lead product candidates for the treatment of CF include PTI-801, a third generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Proteostasis Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 7.